Belimumab concentration measurements using a homologous anti-idiotype immunoassay.

Autor: Loeff FC; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., Parodis I; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Walhelm T; Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden., Jönsen A; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden., Nikolopoulos D; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden., Sjöwall C; Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden., Bengtsson AA; Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden., Kos D; Sanquin Reagents B.V., Amsterdam, the Netherlands., van Leeuwen A; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., van den Broek B; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., Dijk L; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., Jeremiasse J; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands., Blomjous BS; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands., Voskuyl AE; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands., Wolbink GJ; Amsterdam Rheumatology and immunology Center|Reade, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands., Bultink IEM; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands., Rispens T; Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: t.rispens@sanquin.nl.
Jazyk: angličtina
Zdroj: Journal of immunological methods [J Immunol Methods] 2024 Sep; Vol. 532, pp. 113717. Date of Electronic Publication: 2024 Jul 02.
DOI: 10.1016/j.jim.2024.113717
Abstrakt: Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic monoclonal antibodies. A particularly useful format involves the use of anti-idiotype monoclonal antibodies, selected to be highly specific to the antibody of interest. Here, we describe the development of a specific, high-affinity anti-idiotype antibody to belimumab, and the application of this antibody in a homologous sandwich ELISA to measure belimumab concentrations.
(Copyright © 2024 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: